Staying focus BIT:
- A library over 300 compounds with activity against a range of viruses, witch form the starting point for designing potent inhibitor specific point for design for viruses interest.
- pipeline, program indications with high unmet clinical need or large patients populations such as hepatitis c, HIV v clinical and dangue, zika influenza.
- robust clinical validation, completed 7 human clincial trials with strong, safety and efficacy outcomes.
- portfolio of patients and pentent applications directed to visitor's unique anti viral approach and each product candidt.
- pipe line :
Hep C compound BIT225 - 2 x phase II studies completed.
HIV-1 / HCV compound BIT225 - 1 x phase II study completed.
HIV- 1 BIT225 1 x phase study completed.
Next gen Hep c - discovery successfull, preclinical successfully. Phase 1 phase phase 2 still on going.
Dengue, influenza, zika - discovery suscusfull, preclincal / phase 1 / phase 2 still on going.
more key words: potential partners, page-157
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
3.6¢ |
Change
-0.011(23.4%) |
Mkt cap ! $32.48M |
Open | High | Low | Value | Volume |
4.8¢ | 4.8¢ | 3.5¢ | $444.5K | 11.21M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 459179 | 3.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.9¢ | 71980 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 459179 | 0.036 |
2 | 72512 | 0.035 |
1 | 100000 | 0.033 |
2 | 62500 | 0.032 |
1 | 90000 | 0.031 |
Price($) | Vol. | No. |
---|---|---|
0.039 | 71980 | 2 |
0.040 | 927370 | 1 |
0.041 | 44000 | 1 |
0.042 | 129600 | 2 |
0.043 | 200000 | 1 |
Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |